In chronic Budd–Chiari on long-term anticoagulation after stenting with thrombocytopenia and portal hypertensive bleeding risk, what clinical/laboratory thresholds make you comfortable choosing a direct oral anticoagulant instead of a vitamin K antagonist, and what is your monitoring/switch strategy if hepatic function or bleeding risk worsens?